Data coverage, completeness and provenance for STARPHARMA HOLDINGS LIMITED in the Stock Market API — Health Care · Biotechnology.
Source date: 2026-10-30T05:10:11. Source: yfinance. Collection time is shown separately and does not establish a trade date.
| Date | Close | Currency | Source | Adjustment basis |
|---|---|---|---|---|
| 2026-10-30 | 0.4500 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-29 | 0.4300 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-28 | 0.4600 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-27 | 0.4450 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-26 | 0.4750 | AUD | yfinance | Split- and dividend-adjusted close |
GET /api/v1/companies/SPL/prices · Price parameters and adjustment semantics
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial. In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; DEP technology for antibody-drug conjugates; and SPL7013 for vaginal gel, a treatment of bacterial vaginosis and prevention of recurrent BV, and an antiviral condom. It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma's dendrimer technology. Starpharma Holdings Limited was incorporated in 1997 and is based in Abbotsford, Australia.
Employees: 50 · Website: https://starpharma.com · Profile fields populated: 75%
Share of stored fields populated in the anchor reporting period (FY2026), primary source yfinance. Full per-field breakdown: GET /api/v1/companies/SPL/financials.
Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.
| Period | Period end | Revenue | Net income | Total assets | Total equity | Fields populated | Source |
|---|---|---|---|---|---|---|---|
| FY2026 (AUD) | 2026-06-30 | 28 | yfinance | ||||
| FY2025 (AUD) | 2025-06-30 | 29 | yfinance | ||||
| FY2024 (AUD) | 2024-06-30 | 29 | yfinance | ||||
| FY2023 (AUD) | 2023-06-30 | 29 | yfinance |
The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.
Name, sector, industry, HQ, employees, market cap, source-tagged.
GET /api/v1/companies/SPL
Multi-year statements with per-field source tags and completeness.
GET /api/v1/companies/SPL/financials
P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.
GET /api/v1/companies/SPL/metrics/summary
Report PDFs with LLM-ready markdown conversions where available.
GET /api/v1/companies/SPL/filings
Dated press releases and announcements with source links.
GET /api/v1/companies/SPL/news
Create a free key, then:
curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/SPL
Free tier — instant API key. Built for AI agents.